Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide plus Akkermansia muciniphila in obese patients with type 2 diabetes mellitus
ChiCTR2500101690Phase 4Not yet recruiting
- Sponsor
- The Fifth Hospital of Xiamen
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide, akkermansia muciniphila and metformin in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by The Fifth Hospital of Xiamen. Primary endpoints: Body weight, Visceral adiposity index (VAI) and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2500101690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101690.